12,372 trials
Male Osteoporosis
Primary: Percentage of Participants With at Least One New Morphometric Vertebral Fracture Over 24 Months — 1.6; 4.9 Percentage of Participants
Breast Cancer
Primary: Time to Disease Progression (TTP) Using Response Evaluation Criteria in Solid Tumors (RECIST) — 6.02; 6.05; 6.58; 7.10 Months — p=0.6686
Cataract
Primary: Best Corrected Distance Visual Acuity — 119; 120 participants
Healthy
Primary: Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Overall Population — 124; 62; 1333; 215 titer
Lower Back Pain
Primary: Subject Rating of Pain on a 100-point Visual Analog Scale (VAS) — 27.5; 28; 28.6 mm
Infection, Human Immunodeficiency Virus
Primary: Number of Participants With Any Adverse Event (AE): Interim Analysis — 117; 16; 215; 52 participants
Osteoporosis
Primary: Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Tomography (QCT) at 18 Months — 12.28; 2.94 milligram…
Chronic Obstructive Pulmonary Disease (COPD)
Primary: The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment — 1; 0; 0; 0 Participants
Seizures
Primary: Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)…
Chronic Hepatitis C
Primary: Alanine Aminotransferase at Baseline — 109.2; 106.3; 110.6 IU/L
Type 2 Diabetes
Primary: Safety and Tolerability of Sitagliptin After 4 Weeks of Treatment — 5; 5; 0; 0 Participants
Ankylosing Spondylitis
Primary: Number of Participants Meeting the Assessment of Spondyloarthritis International Society (ASAS) ASAS20 Response Criteria — 154; 35 participants — p=< 0.001
Rhinitis, Allergic, Perennial
Primary: Change From Baseline in the Total Nasal Symptom Score at 2 Weeks — -3.9850; -1.9081 score on a scale — p=<0.0001
Herpes Simplex Infection
Primary: Number of Subjects With Newly Acquired Genital Herpes Disease, Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2 — 35; 35 Subjects
Ovarian Cancer
Primary: Progression Free Survival (PFS) as Determined by the Investigator, Per Response Evaluation Criteria for Solid Tumors (RECIST) — 12.4; 8.4 Months — p=<0.0001